Opinion
Video
Examining Treatment Algorithms for MDS
Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome.
The discussion centered on diverse treatment strategies for myelodysplastic syndrome (MDS), focusing on intermediate and high-risk patients. Ruemu Birhiray, MD, highlighted how disease heterogeneity impacts treatment options, emphasizing distinctions in managing low versus intermediate-risk MDS. The primary goals included preventing acute leukemia, restoring bone marrow function, and prolonging patient survival. He detailed the effectiveness of "hypomethylating agents" like azacitidine and decitabine, clarifying their mechanism in gene silencing reversal to improve marrow function. These agents, both intravenous and oral, demonstrated efficacy in MDS treatment. The conversation also delved into stem cell transplantation's limitations due to higher risks in low-risk patients, highlighting transplant candidacy challenges in the elderly or those with comorbidities.
Moreover, the talk addressed unique MDS subsets. The 5q- deletion syndrome showed responsiveness to lenalidomide, while hypoplastic MDS patients might benefit from immunosuppressive agents. Tracey Iraca emphasized the critical role of supportive care—transfusions, growth factors, and prophylactic antibiotics—to manage symptoms. The challenge lay in quantifying external transfusions and ensuring the efficacy of supportive care. Understanding patient-reported outcomes and modifying treatment based on comprehensive patient care remained crucial. Ultimately, the team highlighted the significant impact of symptom control and disease management on patients' quality of life, fostering a holistic approach to MDS care.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
